Regeneron Pharmaceuticals got a modest confidence bump as Mirae Asset Global ETFs Holdings added 1,712 shares to their ...

Regeneron Pharmaceuticals has promised to comply with 23andMe's existing privacy polices while also using data to fuel drug discovery.

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...

Regeneron Pharmaceuticals agreed to buy DNA testing company 23andMe in a bankruptcy court auction, the company said Monday.

Genetic testing company 23andMe filed for Chapter 11 bankruptcy protection in March. Regeneron Pharmaceuticals announced it would buy "substantially all" of 23andMe's assets.

Regeneron Pharmaceuticals announced Monday it plans to purchase human genetics and biotechnology firm 23andMe from bankruptcy ...

Mufg Securities Americas Inc. made a modest splash in the biotech pool, acquiring 1,554 shares of Regeneron Pharmaceuticals ...

Regeneron said it will continue uninterrupted service of 23andMe’s consumer genome services after its purchase closes as ...

Regeneron said it will acquire 23andMe’s genomics service and its bank of 15 million customers’ personal and genetic data as part of the deal. The pharma giant said it plans t ...

Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., May 14, 2025. REUTERS/Brendan McDermid A batch of U.S. retail earnings reports in the coming week is set to ...

Regeneron’s gene therapy for a profound form of deafness affecting children, DB-OTO, has shown the first signs that it can improve hearing in a clinical trial. The promising finding, in one ...